

ADVENTRX PHARMACEUTICALS INC

Form 8-K

April 06, 2006

Table of Contents

**UNITED STATES SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**FORM 8-K**

**CURRENT REPORT PURSUANT  
TO SECTION 13 OR 15 (d) OF THE  
SECURITIES EXCHANGE ACT OF 1934**

**Date of Report (Date of earliest event reported) April 3, 2006**

**ADVENTRX Pharmaceuticals, Inc.**

(Exact name of registrant as specified in its charter)

**Delaware**

(State or other jurisdiction of incorporation)

**001-32157**

(Commission File Number)

**84-1318182**

(IRS Employer Identification No.)

**6725 Mesa Ridge Road, Suite 100**

**San Diego, California 92121**

(Address of principal executive offices) (Zip Code)

**(858) 552-0866**

(Company's telephone number, including area code)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
  - Soliciting material pursuant to rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
  - Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
  - Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
-

**TABLE OF CONTENTS**

Item 8.01. Other Events

Item 9.01. Financial Statements and Exhibits

SIGNATURES

EXHIBIT INDEX

EXHIBIT 99.1

EXHIBIT 99.2

---

**Table of Contents**

**Item 8.01. Other Events.**

On April 3, 2006, the Company announced that positive preclinical testing results showing strong antiviral synergy without added cytotoxicity with combinations of Thiovir and zidovudine (AZT) were presented at the HIV Pathogenesis Meeting in Keystone, Colorado on March 31, 2006.

On April 5, 2006, the Company announced that it presented preclinical study results showing an improved toxicity profile for its oncology compound, ANX-530 (vinorelbine emulsion) at the American Association for Cancer Research (AACR) 97th Annual Meeting 2006 on April 5, 2006.

The press releases issued by the Company on April 3 & 5, 2006 with respect to these matters are included with this report as exhibits.

**Item 9.01. Financial Statements and Exhibits.**

(99) (c) The exhibit list required by this item is incorporated by reference to the Exhibit Index filed as part of this report.

---

**Table of Contents**

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

**ADVENTRX Pharmaceuticals, Inc.**

**By:** /s/ Carrie E. Carlander

**Name:** Carrie E. Carlander  
**Title:** Chief Financial Officer,  
Senior Vice President Finance,  
Secretary and Treasurer

April 6, 2006

---

**Table of Contents**

EXHIBIT INDEX

Exhibit	Description
99.1	Press Release of the Company dated April 3, 2006.
99.2	Press Release of the Company dated April 5, 2006.